Allegion Schedules Webcast to Announce 2026 Second-Quarter Results
Get Alerts ALLE Hot Sheet
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 1.6%
EPS Growth %: +8.3%
Join SI Premium – FREE
DUBLIN--(BUSINESS WIRE)-- Allegion plc (NYSE: ALLE), a leading global security products and solutions provider, will release its 2026 second-quarter financial results on Thursday, July 23, before the market opens.
Later that morning, John H. Stone, president and CEO, and Mike Wagnes, senior vice president and chief financial officer, will conduct a conference call for analysts and investors, beginning at 8 a.m. ET, to review the company's results.
The real-time webcast and a replay of the event will be made available through the company’s investor website at investor.allegion.com or directly by clicking here.
About Allegion
At Allegion (NYSE: ALLE), we design and manufacture innovative security and access solutions that help keep people safe where they live, learn, work and connect. We’re pioneering safety with our strong legacy of leading brands like CISA®, Interflex®, LCN®, Schlage®, SimonsVoss® and Von Duprin®. Our comprehensive portfolio of hardware, software and electronic solutions is sold around the world and spans residential and commercial locks, door closer and exit devices, steel doors and frames, access control and workforce productivity systems. Allegion had $4.1 billion in revenue in 2025. For more, visit www.allegion.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260709649821/en/
Media Contact:
Whitney Moorman – Director, Global Communications
317-810-3241
[email protected]
Analyst Contact:
Jobi Coyle – Director, Investor Relations
317-810-3107
[email protected]
Josh Pokrzywinski – Vice President, Investor Relations
463-210-8595
[email protected]
Source: Allegion plc
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- EU proposes to curb Airbnb and short-term rentals amid housing shortage
- TORRAS Introduces Ostand Q3 Air Pro as Its Second Flagship Case for iPhone 18
- ETCAMAH® (camizestrant) in combination with a CDK4/6 inhibitor approved in the US for 1st-line advanced HR-positive breast cancer
Create E-mail Alert Related Categories
Business Wire, Press ReleasesRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share